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Epilepsy-associated GRIN2A 
mutations reduce NMDA receptor 
trafficking and agonist potency – 
molecular profiling and functional 
rescue
L. Addis  1,2, J. K. Virdee2, L. R. Vidler2, D. A. Collier  2, D. K. Pal1 & D. Ursu2
Mutations in the N-methyl-D-aspartate receptor (NMDAR) gene GRIN2A cause epilepsy-aphasia 
syndrome (EAS), a spectrum of epileptic, cognitive and language disorders. Using bioinformatic 
and patient data we shortlisted 10 diverse missense mutations for characterisation. We used high-
throughput calcium-flux assays and patch clamp recordings of transiently transfected HEK-293 cells for 
electrophysiological characterization, and Western blotting and confocal imaging to assay expression 
and surface trafficking. Mutations P79R, C231Y, G483R and M705V caused a significant reduction in 
glutamate and glycine agonist potency, whilst D731N was non-responsive. These mutants, along with 
E714K, also showed significantly decreased total protein levels and trafficking to the cell surface, whilst 
C436R was not trafficked at all. Crucially this reduced surface expression did not cause the reduced 
agonist response. We were able to rescue the phenotype of P79R, C231Y, G483R and M705V after 
treatment with a GluN2A-selective positive allosteric modulator. With our methodology we were not 
able to identify any functional deficits in mutations I814T, D933N and N976S located between the 
glutamate-binding domain and C-terminus. We show GRIN2A mutations affect the expression and 
function of the receptor in different ways. Careful molecular profiling of patients will be essential for 
future effective personalised treatment options.
The epilepsy-aphasia spectrum (EAS) represents a continuum of genetic epilepsy syndromes with the EEG sig-
nature of focal sharp waves, concurrent with various speech and language disorders1, 2. At the mild end is the 
common childhood disorder of Rolandic epilepsy (RE), frequently associated with speech and oromotor deficits, 
as well as reading disability, attention, and memory problems3. Focal seizures commonly occur during sleep and 
the defining electroencephalographic (EEG) abnormality is blunt centrotemporal spikes (CTS) during sleep4. 
Atypical benign partial epilepsy (ABPE) is much more rare, consisting of more severe seizures as well as some 
regression of speech, motor skills and attention5. The debilitating disorders of epileptic encephalopathy of con-
tinuous spike-and-waves during slow-wave sleep (ECSWS) and Landau-Kleffner syndrome (LKS) represent the 
more severe, and less-frequent, end of the spectrum. There is catastrophic loss of receptive and expressive lan-
guage in children who develop LKS and who were, in general, previously cognitively normal. The EEG evolves 
into continuous spike-and-waves during slow-wave sleep (CSWS)6, with easily controlled Rolandic seizures. In 
ECSWS, the epilepsy is often refractory to treatment, with multiple seizure types present. Children with ECSWS 
have global regression across learning, memory, motor and social skills7.
Until relatively recently the aetiology of most EAS disorders was largely unknown, although environmen-
tal factors such as thalamic injury can cause the EEG phenotype8. CTS in RE is associated with variants in 
PAX6-ELP4 on 11p139, 10, and rare mutations and deletions in the N-methyl-D-aspartate receptor (NMDAR) 
genes have been reported in families with mental retardation and various epilepsy phenotypes11–14. In 2013 three 
groups simultaneously discovered mutations and small deletions of GRIN2A across EAS disorders15–17. GRIN2A 
1Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College 
London, London, UK. 2Neuroscience Discovery, Eli Lilly Research Centre, Windlesham, Surrey, UK. Correspondence 
and requests for materials should be addressed to L.A. (email: laura.addis@kcl.ac.uk)
Received: 29 September 2016
Accepted: 6 February 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 66  | DOI:10.1038/s41598-017-00115-w
encodes the GluN2A subunit of the NMDAR, a transmembrane ligand-gated ion channel with a critical role 
in normal neuronal development, synaptic plasticity and memory. Disturbances of NMDARs are implicated in 
disorders such as schizophrenia and Alzheimer’s disease and represent targets of interest for pharmacological 
treatments18, 19. NMDARs are hetero-tetramers, usually consisting of two GluN1 and two GluN2 (A-D) subu-
nits, creating many receptor subtypes with distinct properties, functions and expression levels14, 19. NMDARs 
are activated following the binding of glycine and glutamate to the GluN1 and GluN2 subunits respectively. This 
then opens the cation-selective pore, allowing intracellular Ca2+ influx when the Mg2+ blockade is removed upon 
membrane depolarisation. NMDARs consist of four domains: the extracellular amino (N)-terminal domain 
(NTD) involved in subunit assembly and allosteric modulation, (Fig. 1a), the agonist-binding domain (ABD), 
the transmembrane domain (TMD), and the intracellular C-terminal domain (CTD) involved in receptor 
trafficking14.
Here we present an in vitro functional analysis of 10 missense mutations of GRIN2A identified in children 
with EAS disorders15–17. Our studies reveal variable phenotypes ranging from loss of receptor trafficking, through 
altered agonist potency to total loss of function. We were able to rescue the phenotype of mutations with reduced 
glutamate potency following treatment with a GluN2A-selective positive allosteric modulator. This work indicates 
careful molecular analysis of GRIN2A patient mutations is important before starting targeted treatment options.
Results
Bioinformatic analysis and selection of GRIN2A patient mutations. Over 30 GRIN2A missense 
mutations have been identified in EAS patients15–17. We assigned Combined Annotation Dependent Depletion 
(CADD) scores20 to these mutations to create predictions of deleteriousness based on measures such as conser-
vation metrics and protein structure. These CADD scores were compared to those for controls from the Exome 
Variant Server (EVS), (Fig. 1b). All EAS-associated variants apart from N976S are located above the CADD-
20 cut off for the 1% most deleterious variants, and 26/31 are located within the NTD, ABD or pore domains. 
Variants from EVS controls either largely score below CADD-20 or are located within the C-terminus where they 
are predicted to cause less severe functional effects.
We selected 10 EAS-associated missense mutations for further analysis from different functional domains, 
with different inheritance patterns (de novo vs inherited and segregating with disease), disease outcomes and a 
range of CADD scores (Table 1 and Fig. 1). A contribution to the selection of the mutants was hypothesis driven, 
based on analysis of crystal structures, (Fig. 1c).
Selected GRIN2A mutations protect against NMDA receptor toxicity. We carried out site-directed 
mutagenesis in the human GRIN2A cDNA to create the 10 mutation constructs, which were subsequently 
inserted into the expression plasmid pcDNA3.1(+) before transfection into HEK-293 cells along with GRIN1 
in a second pcDNA3.1(+) plasmid. To allow identification of the transfected cells an HA-tag was added to the 
N-terminus, which did not alter the function of the receptor (Supplementary Fig. 1) and this construct was sub-
sequently called Wild Type (WT).
Free glutamate and glycine in culture media is toxic to HEK cells transfected with NMDAR from direct influx 
of calcium through the activated channels21. Using a continuous live-cell imaging system we were able to leverage 
this characteristic to carry out a screen for GluN2A mutant functionality. After 48 hours almost all of the WT 
GluN2A cells were dead, compared to very few of those co-transfected with the control empty vector and GRIN1, 
which were spread out and dividing. Some mutants showed an intermediate phenotype (Fig. 2a). Cells transfected 
with the WT GRIN2A receptor die at an accelerated rate compared to those that are untransfected (UT) or trans-
fected with an empty vector after only 12 hours (Fig. 2b). This indicates the rapid expression and trafficking of 
the NMDAR to the cell surface, the binding of glutamate present in the media and the subsequent calcium influx 
and excitotoxicity. Analysis of the GluN2A mutants shows a similar mortality rate to WT for E714K, D933N and 
N976S indicating similar functionality, (Fig. 2c). All other mutants were significantly different to the WT con-
struct (Dunnett’s corrected AVOVA, p < 0.001). I814T and M705V appear to have an intermediate phenotype, 
followed by G483R and P79R with less than 75% of cells dying after 48 hours. A level of mortality consistent with 
cells transfected with the empty vector is shown for C231Y, C436R and D731N.
GRIN2A mutations can decrease agonist potency. The results of the cell toxicity assay indi-
cated that some mutants potentially alter GluN2A glutamate potency and/or receptor expression. We used 
fluorescence-based single-cell calcium-flux imaging to investigate agonist pharmacology in more detail in 
transiently transfected HEK cells22, 23. Four mutants, P79R, C231Y, C483R and M705V significantly decrease 
glutamate potency (F1,63 = 459.1, F1,55 = 427.3, F1,43 = 987.6 and F1,43 = 160.9 respectively, Bonferroni corrected 
ANOVA, p < 0.0001), (Fig. 3a–c), as shown by the increase in the half-maximally effective concentration of ago-
nist (EC50) (Table 2). Two mutations, C436R and D731N produced no detectable response to maximal glutamate 
or glycine, (Fig. 3c,e). Four of the mutations did not alter the response to glutamate, E714K, I814T, D933N and 
N976S, when compared to WT, (Fig. 3d). The effects on glycine potency of the GRIN2A mutations were similar 
to those recorded for glutamate with P79R, C231Y, C483R and M705V producing significant decreases in glycine 
potency compared to WT receptors (F1,36 = 246.2, 539.7, 347.2 and 116.3 respectively, p < 0.0001), (Fig. 3e,f and 
Table 2). These shifts in glutamate and glycine potency are not due to saturation of the Fluo-4AM calcium dye, 
as use of the higher-affinity Fluo-2AM did not alter the CRC curves (data not shown). Single cell patch clamp 
recordings of HEK cells transfected with G483R-GRIN2A and GRIN1 gave very similar results to the calcium-flux 
imaging, (Fig. 3g,h).
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Figure 1. CADD scores and protein modelling predict stronger functional effects for EAS-associated GRIN2A 
mutations than in controls. (a) Protein structure model of NMDAR (PDB ID 4TLL): GluN1 (grey and green), 
GluN2 (B in this structure) (blue and red). Membrane would be horizontal in this image with the NTD and 
ABD in the extracellular space. Intracellular C-Terminal domain would be below the transmembrane domain 
(not present in this structure). (b) Schematic linear representation of GluN2A with the domains annotated. 
Black rectangles indicate transmembrane domains. Plot of scaled CADD scores against GluN2A amino acid 
position for missense variants. Black dots represent scores for 65/6474 individuals from the Exome Variant 
Server (EVS) that had missense variants in GRIN2A and coloured symbols are scores for variants found in 
individuals with EAS disorders. The horizontal dotted line indicates the scaled CADD score cut off of 20 for a 
highly likely deleterious variant. (c) Protein structure model of the NTD of NMDAR (PDB ID 3QEL): GluN1 
(grey), GluN2 (B in this structure) (red). Mutations considered in this domain highlighted (conserved between 
GluN2A and B). (d) Protein structure model of the LBD of NMDAR (PDB ID 2A5T): GluN1 (grey), GluN2A 
(blue). Mutations considered in this paper highlighted, as well as agonists.
cDNA alteration Protein alteration Phenotype Inheritance, Segregation (Y/N) CADD Scaled Score Reference
c.236C > G P79R RE/ECSWS Maternal, Y 24.9 16
c.692G > A C231Y LKS Maternal, Y 26.7 16
c.1306T > C C436R ABPE de novo 27 16
c.1447G > A G483R ECSWS, aRE Maternal, N 34 17
c.2113A > G M705V RE Maternal, Y 25.6 16
c.2140G > A E714K ECSWS Unknown 23.4 16
c.2191G > A D731N aRE, VD Maternal, VD -Y 26.6 17
c.2441T > C I814T RE Paternal, N 21.5 16
c.2797G > A D933N LKS Paternal, N 28 17
c.2927A > G N976S
ECSWS Unknown
7.2 16
ABPE Unknown
Table 1. Summary of clinical and genetic information for studied GRIN2A mutations. cDNA annotation 
based on the canonical transcript ENST00000396573. Phenotype abbreviations as follows: ABPE – atypical 
benign partial epilepsy, aRE – atypical Rolandic epilepsy, CSWS – epileptic encephalopathy with continuous 
spike and wave during slow wave sleep, LKS – Landau-Kleffner Syndrome, RE – Rolandic epilepsy, VD – 
verbal dyspraxia. Y-yes, N-no for segregation of variants with phenotype. CADD score stands for “combined 
annotation dependent depletion”, a tool for scoring the deleteriousness of single nucleotide variants and were 
generated using v1.3 on 19 May 2016 from http://cadd.gs.washington.edu/. A score > 20 indicates the top 1% 
most deleterious substitutions20.
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GRIN2A mutations can alter total levels of GluN2A protein. Ion channel mutations often cause 
reduced protein expression due to degradation of misfolded proteins within the endoplasmic reticulum (ER) 
quality control pathway. Using single-cell calcium-flux imaging we investigated if the percentage of HEK cells 
with NMDARs responding to glutamate changed with mutation type. This was achieved by first perfusing the 
cells with a maximal glutamate concentration to activate NMDAR expressing cells, and then a maximal MgATP 
concentration to induce intracellular calcium release via P2Y purinergic receptors found on all HEK cells24. 
Figure 4a show example data for cells transfected with the WT plasmid, where 81% (±2.7% SEM) responded 
to maximal glutamate. This also shows the transfection efficiency of the plasmids. There was no significant dif-
ference for E714K, I814T, D933N and N976S, mutants with no altered glutamate potency. The two mutants who 
did not respond to glutamate, C436R and D731N, again showed no response here (Dunnett’s corrected one-way 
ANOVA, F9,51 = 23.01, p < 0.001). Interestingly the responses differ for the mutants with decreased glutamate 
potency, but do not directly correlate with the severity of the agonist potency change; 75% (±5.7%) of P79R 
cells responded to glutamate (not significant), 61% (±6.3%) of G483R (not significant), 49% (±15%) of M705V 
(p < 0.01) and 18% (±6.4%) of C231Y (p < 0.001), (Fig. 4b–e), indicating protein degradation and/or trafficking 
are altered here as well in these mutants.
Figure 2. Selected GRIN2A mutations protect against glutamate-induced toxicity in HEK cells. (a) 
Superimposed bright field and pseudocolour red images, indicating fluorescent Cytotox Red dye in dead cells, 
of HEK cells transiently transfected with various GRIN2A mutant constructs, or empty vector. Free glutamate 
and glycine in the culture media causes cell death in those expressing functional NMDARs over 48 hours. 
Images captures at 20x using the IncuCyte live-cell imaging system. (b) Representative time course of cell death, 
normalised to initial confluency in each well, n = 5 wells, Mean ± SEM. (c) Plot of cell mortality for GRIN2A 
mutants normalised to initial confluency per well. Mutants P79R, C231Y, C436R, G483R, M705V, D731N and 
I814T are protective against glutamate toxicity either due to reduced trafficking and/or reduced functionality 
of the receptors. ***p < 0.001 Dunnett’s corrected one-way ANOVA. Averaged data from n = 15 wells per 
construct except for G483R, E714K, D933N and N976S where n = 12 wells, 3 × 104 cells/well. Mean ± SEM.
www.nature.com/scientificreports/
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Figure 3. GRIN2A mutations alter the response to glutamate and glycine. (a,b) Pseudocolour images and 
representative single-cell traces from calcium-flux imaging for HEK cells transfected with either WT or 
G483R GRIN2A showing different calcium responses caused by the application of increasing concentrations 
of glutamate (30 nM–30 µM red arrows). Individual cell traces in cyan and the mean response in red. (c,d) 
Normalised concentration response curves (CRCs) to increasing concentrations of glutamate from single cell 
calcium-flux imaging. In (c) 4 mutants; P79R, C231Y, C483R and M705V have reduced agonist potency, while 
C436R and D731N show no response to glutamate. Four mutant constructs (d), show an unaltered response 
to glutamate. (e,f) Normalised CRCs to increasing glycine concentration with constant 3 µM glutamate – the 
mutations show similar responses as to glutamate. See Table 2 for n to create averaged data per construct, 3 × 104 
cells/well. Error bars ± SEM. (g) Representative continuous voltage-clamp recordings obtained from HEK cells 
transfected with WT or G483R GRIN2A plasmid. Bars above the recording indicate glutamate application (co-
applied with 30 µM glycine). Application of increasing concentrations of glutamate shows a progressive increase 
in current observed, the sensitivity of which is shifted to higher concentrations of glutamate in the G483R 
mutant compared to WT. (h) Normalised CRC to glutamate as recorded in (g) indicates the same response as 
for single cell calcium imaging (n = 3).
www.nature.com/scientificreports/
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Western Blotting of total cell lysates from the transfected HEK cells show that GluN2A total protein levels 
were greatly reduced for most of the mutants, with the lowest relative expression for the two that alter cysteine 
residues, C231Y (31% ± 6.1) and C436R (18% ± 6.9), (Fig. 5a,b).
GRIN2A mutations can alter GluN2A membrane trafficking. Functional checkpoints in the ER can 
limit forward trafficking of NMDA receptors to the cell surface14. As many mutants reduce total GluN2A pro-
tein levels, we wanted to ascertain if they also reduced cell surface expression. Co-transfected HEK cells were 
fixed with, and without membrane permeabilisation, and incubated with anti-HA-tag antibody, which would 
ensure binding to the extracellular part of the NMDAR receptor. The average intensity of labelled surface receptor 
immunofluorescence and of total GluN2A immunofluorescence was calculated for each mutant (Fig. 5c,d)25. 
The immunocytochemistry data explains why cells transfected with mutant C436R do not respond to gluta-
mate – the protein does not traffic to the cell membrane (Dunnett’s corrected one-way ANOVA F10,55 = 6.01, 
p < 0.001). However for D731N some protein does reach the surface of some cells, although is still significantly 
reduced (p < 0.001), but for this mutant it does not respond to glutamate or glycine. Three of the four mutants 
with reduced agonist potency, P79R, C231Y and G483R, all have significantly reduced membrane expression 
(p < 0.001), which is also only present in a very small number of cells. G483R also has significantly reduced total 
expression, p < 0.001). The reduction of surface expression for M705V is not significant. Interestingly, E714K has 
a similar level of surface expression to M705V; however, the E714K receptors that reach the cell surface appear to 
have a normal agonist response, whereas for M705V they do not. Mutants E714K, I814T, D933N and N976S also 
did not show a significant change in surface or total protein labelling.
The relative level of cell surface expression of the mutant GluN2A constructs correlates well with the gluta-
mate EC50 (Fig. 5e). Our results suggest that ligand binding affinity is not determined by cell surface expression. 
Figure 5f shows that transfection of HEK with 25% less WT GRIN2A plasmid compared to the normal 320 ng/
well does not alter the response to glutamate. There is a small shift when 12.5% of the plasmid is used, but this 
does not then shift further at 6.25%, and is much smaller than the significant shift seen for P79R, where the aver-
age intensity of surface expression is 30% of WT levels.
Pharmacological rescue of function can be achieved for selected GRIN2A mutants. A standard 
approach for rescuing loss of function phenotypes, as observed here, is the use of pharmacological modulators 
to enhance receptor function. We hypothesized that mutations which reduce agonist potency could have their 
function rescued by a selective positive allosteric modulator (PAM). We chose a GluN2A-selective compound 
recently disclosed in a patent application (compound 275 in ref. 23, GluN2A EC50 12 nM). Initial assays indicated 
that pre-incubation for 1 minute followed by co-application of 1 µM of the PAM alongside a lower concentration 
of glutamate significantly increased the calcium influx for the wild type and mutant receptors (Bonferroni cor-
rected one-way ANOVA, F7,10 = 55.25, p < 0.001 for WT, P79R and C231Y, G483R is not significant) (Fig. 6a–c 
and Supplementary Fig. S2). The agonist potency of these mutants was then partially or fully restored to WT 
levels in the presence of 1 µM PAM followed by sequential addition of increasing concentrations of glutamate 
(Fig. 6d–h). The EC50 for P79R decreased from 1.45 to 0.13 µM (F1,97 = 497.5, p < 0.0001) (WT EC50 is 0.42 µM), 
C231Y from 1.89 to 0.26 µM (F1,77 = 209.2, p < 0.0001), G483R from 11.30 to 1.37 µM (F1,87 = 484.3, p < 0.0001) 
and M705V from 0.89 to 0.03 µM (F1,91 = 500.6, p < 0.0001). The PAM did not have an effect on mutant D731N 
or C436R (data not shown).
Discussion
In this study we have carried out a functional analysis of 10 disease-associated missense mutations of GRIN2A 
that were chosen by a bioinformatics and patient-centric approach, and have uncovered a range of molecu-
lar consequences. GRIN2A mutations in EAS are spread across the gene and our work, combined with others 
where EAS- or early-onset epileptic encephalopathy associated GRIN2A mutations (studied generally in the 
Mutation
Glutamate EC50 µM, 
95%CI (n)
Glycine EC50 µM, 
95%CI (n)
WT 0.42, 0.40–0.47 (16) 0.55, 0.50–0.61 (12)
P79R 1.45, 1.35–1.57 (15)*** 1.53, 1.37–1.70 (11)***
C231Y 1.89, 1.71–2.10 (17)*** 4.13, 3.86–4.42 (13)***
C436R — —
G483R 11.30, 10.1–12.65 (12)*** 3.50, 3.01–4.08 (12)***
M705V 0.89, 0.78–1.02 (12)*** 1.31, 1.11–1.53 (11)***
E714K 0.41, 0.38–0.45 (12) 0.78, 0.72–0.85 (13)
D731N —
I814T 0.42, 0.38–0.44 (9) 0.58, 0.50–0.67 (10)
D933N 0.41, 0.38–0.44 (9) 0.68, 0.62–0.75 (10)
N976S 0.37, 0.32–0.43 (9) 0.71, 0.60–0.83 (11)
Table 2. Summary of Glutamate and Glycine EC50 for wild type and mutant GluN2A constructs. Data 
expressed as mean (95% confidence intervals). N = number of wells from the single cell calcium imaging 
assays (3–6 assays). When no values are given this is because there was no detectable response. ***P < 0.0001 
Bonferroni corrected extra-sum-of-squares F-test of best-fit values of LogEC50.
www.nature.com/scientificreports/
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homozygous state) have been shown to affect zinc sensitivity16, 26, increase glutamate potency27, 28, alter channel 
gating kinetics17, 28 or eliminate the Mg2+ block11, indicate a complex pathophysiological picture. Whilst there 
appears to be a clear rational for alteration of function in some cases, such as substitution of a cysteine resi-
due leading to drastic changes in protein folding and degradation (e.g. C436R here), or substitution of a zinc 
binding residue slowing zinc dissociation kinetics e.g. R370W in26, in other cases further understanding of the 
structure-function relationships of the NMDAR are needed, such as why L812M in the linker region between the 
ABD and TM domains enhances agonist potency28, whereas I814T studied here, has no effect on agonist potency.
Three mutants have a “double hit” of significantly reduced agonist potency and surface expression; P79R, 
C231Y and G483R. They were found in children with the most severe EAS subtypes, ECSWS and LKS. M705V 
also disrupts in a similar manner but to a lesser extent, and is found in a child with less severe Rolandic epilepsy.
Residue G483 occurs on a flexible loop and seems important in the structure of the glutamate binding site, 
which would be restricted by the change to the large, positive arginine residue. Previously, site directed mutagen-
esis of the neighboring residue K484 to aspartic acid reduced glutamate affinity 6-fold but had no measurable 
effect on glycine binding29. Interestingly K484 is not conserved in GluN1, whereas G483 is. Residue P79, within 
the NTD, is conserved across all GluN paralogues and is predicted to make extensive contact with GluN130. 
Replacement of the proline with the basic arginine residue likely disrupts this contact and the overall NMDAR 
structure, indirectly affecting the binding of glutamate and glycine. Interestingly Serraz et al. also reported that 
Figure 4. GRIN2A mutations alter the number of cells responding to glutamate. (a–d) Each panel contains 
pseudocolour images of HEK cells transfected with WT or mutant GRIN2A showing co-localisation of 
responses to application of 100 µM glutamate +30 µM glycine (green - activation of surface-expressing GluN2A 
receptors) and subsequently 100 µM MgATP (red - activation of endogenous P2Y receptors). Panels also 
show single-cell traces from the same experiment, indicating the different effects of these agonists on cells 
transfected with (a) WT, (b) M705V, (c) C231Y or (d) C436R mutants. Individual cell traces displayed in cyan 
and the mean response shown in red. (e) Ratio of the number of transfected HEK cells responding to 100 µM 
glutamate +30 µM glycine subsequent to 100 µM MgATP. Dunnett’s corrected one-way ANOVA compared to 
WT, **p < 0.01, ***p < 0.001, ns = non-significant. Data averaged from n = 12 wells, 3 × 104 cells/well, for each 
construct over 2 assays. Error bars ± SEM.
www.nature.com/scientificreports/
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Figure 5. GRIN2A mutations reduce total protein levels and membrane trafficking of GluN2A. (a) 
Representative Western blot of HEK lysates probed with anti-GluN2A antibody (top), and anti-GAPDH 
(bottom) as a loading control. Bands around 180 kDa indicate GluN2A. WT, wild type, UT – untransfected. 
Right is Amersham Full-Range rainbow molecular weight marker with the blot imaged in visible light. (b) Plot 
of amount of GluN2A protein, normalised to WT, from Western blotting of total cell lysates of transiently co-
transfected HEK cells 48-hours post transfection. Average of 3 blots from 3 independent transfections. Error 
bars indicated SEM. (c) Fixed and immunolabelled co-transfected HEK cells with anti-HA antibody (red) to 
detect surface GluN2A expression, and fixed, permeabilised and immunolabelled with the same antibody to 
detect total GluN2A protein levels. Scale bar 25 µm. Nuclei stained with Hoechst (blue). (d) Quantitation of 
surface and total GluN2A protein levels, averaged over the total number of cells analyzed for each condition (n 
is between 903 to 2255 cells), reveals greatly reduced surface expression of GluN2A as measured by fluorescence 
intensity. Dunnett’s corrected one-way ANOVA for membrane or total intensity as compared to WT *p < 0.05, 
**p < 0.01, ***p < 0.001, ns = non-significant. Average ± SEM. (e) Relative surface levels of NMDARs 
correlated with the log of glutamate EC50 (Pearson’s coefficient of determination r2 = 0.77, two-tailed p = 0.002). 
(f) Normalised CRC from single-cell calcium-flux imaging. Response to increasing concentrations of glutamate 
from HEK cells co-transfected with decreasing quantities of WT GRIN2A per well (100% = 320 ng) with 
standard 320 ng GRIN1 per well. Response is compared to mutant P79R. Error bars ± SEM.
www.nature.com/scientificreports/
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Figure 6. Pharmacological rescue of functional deficits can be achieved for selected GRIN2A mutants. 
Examples of single-cell imaging of HEK transfected with (a) WT and (b) C231Y mutant showing calcium-
influx response to 300 nM glutamate before and after incubation with 1 µM PAM and in comparison to maximal 
30 µM glutamate. (c) Graph of single cell imaging data showing response of WT and mutants P79R, C231Y and 
G483R to 300 nM glutamate with and without 1 µM PAM. Bonferroni corrected ANOVA ***p < 0.001, n = 15 
wells (over 3 assays) for each construct, 3 × 104 cells/well. Mean ± SEM. (d) Examples of single cell imaging 
of HEK transfected with C231Y mutant showing calcium-influx response to increasing concentrations of 
glutamate (30 nM, 100 nM, 300 nM, 1 µM, 10 µM and 30 µM arrows) top, and below, increasing concentrations 
of glutamate (30 nM, 100 nM, 300 nM, 1 µM and 30 µM arrows) with constant 1 µM PAM. Individual cell 
traces displayed in cyan and the mean response shown in red. (e–h) Concentration response curves of mutant 
(P79R, C231Y, G483R or M705V) GRIN2A transfected in HEK cells to increasing concentrations of glutamate 
(30 nM to 30 µM) during incubation with 1 µM PAM recorded from single-cell calcium-flux imaging. Each 
graph shows the response of the WT GRIN2A construct with no PAM in red (curve from Fig. 3c) and the 
response of the mutant before (solid line) and after (dashed line) the addition of PAM. p < 0.0001 for LogEC50 
for each construct + PAM when compared to without PAM addition. Data averaged from n = 12 wells for each 
construct, 3 × 104 cells/well, (over 3 assays). Error bars ± SEM.
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this mutation decreases zinc sensitivity and enhances proton sensitivity, which they hypothesized was also due to 
the distorted dimer formation between GluN1 and GluN2A26. Whilst Serraz et al. did not detect protein expres-
sion from mutation C231Y over-expressed in oocytes, we detected low levels in transiently transfected HEK-293. 
We identified a reduction in potency of glutamate and glycine due to the change from cysteine to bulky tyrosine 
in a hydrophobic cavity of the NTD. This likely causes protein misfolding, leading to an altered binding pocket 
for agonists and protein degradation. Mutation M705V is located in the ABD, and whilst the substitution is 
for another hydrophobic residue, this residue is conserved between all GluN subtypes and forms part of the S2 
domain of the glutamate binding site (although further away than the other mutations, Fig. 1c).
These four mutations also cause significant reductions in glycine potency. Although glycine binds GluN1, 
interactions between the ligand binding domains of GluN1 and GluN2A can alter agonist binding potency, as 
reported for mutations in the ABD of GluN2A31. Interestingly, mutation E714K did not appear to alter agonist 
potency despite its location within the ABD – most likely because the residue is located on the protein’s surface 
and is not highly conserved. However, this mutation did cause a small, but non-significant reduction in surface 
expression indicating potential changes in protein folding.
Two mutants create a total lack of NMDAR function as di-heteromeric receptors, C436R and D731N. Mutant 
C436R is not present at detectable levels on the cell surface and overall GluN2A protein levels are drastically 
reduced (as also seen in transfected oocytes26). It is likely that the replacement of the cysteine residue with polar 
arginine and breakage of a disulphide bridge causes misfolding and protein degradation for this mutant. This 
most severe mutation effect is seen in a child with ABPE and occurred de novo. On the other hand, mutant 
D731N does show a low level of surface GluN2A, but shows no response to glutamate or glycine. Interestingly, in 
studies of the glycine binding site on GluN1, this same residue (D732) when mutated to alanine, caused 90% of 
the protein to be trapped in the endoplasmic reticulum (ER) upon co-expression with GluN2A and the remain-
der on the cell surface bound glycine with a 4000-fold reduction in potency32, 33. Mutation of D731 to alanine or 
glutamic acid in GluN2A also produced no response in voltage-clamped oocytes33. This residue in GluN2A forms 
a direct contact with glutamate via a salt bridge, which may indicate why such a severe phenotype was observed.
Surface trafficking of ionotropic glutamate receptors seems to require ligand binding to pass a quality control 
checkpoint and exit the ER. Indeed the efficiency of glutamate binding to GluN2B mutant subunits correlates 
with levels of cell-surface receptor and trafficking to synapses. Co-expression with wild-type GluN2B does not 
enhance surface expression, indicating that occupancy of both glutamate binding sites is required for proper 
surface delivery34. The integrity of the glycine binding site of GluN1 is also required for efficient ER exit and cell 
surface trafficking, most likely after GluN1-GluN2 subunit assembly32. Thus, glycine binding to GluN1, and we 
hypothesize given the above work, glutamate binding to GluN2A within the ER, controls forward trafficking of 
the NMDAR to the cell surface. Therefore the patient-derived mutant NMDARs described here, which do not 
bind these agonists effectively, appear to have reduced or absent trafficking, (Fig. 5e).
Haploinsufficieny of GluN2A subunits through reduction in cell surface levels or lack of response to ago-
nists, as described here, may cause hyper-excitable brain networks through several mechanisms. There may be 
a relative excess of GluN2B subunit NMDARs in these patients, and with the slower deactivation time-course 
of GluN2B-containing receptors this could lead to over excitability of the neuronal network35. Activity of 
GluN2A-containing NMDARs is also pivotal in the development and maintenance of the GABAergic function of 
parvalbumin (PV)-positive interneurons36. Thus a reduction in function of GluN2A in these interneurons could 
lead to a poorly functioning inhibitory network. Expression of GluN2A subunits increases postnatally, replacing 
GluN2B at the synapse. This results in a balance of synaptic plasticity and stability that is vital for the maturation 
of associative learning, and dampens hyper-excitation from increased sensory input37. A reduction in GluN2A 
expression during this critical period may create an underdeveloped inhibitory network, again with potential for 
epileptogenicity.
The current study has some limitations. Missense mutations identified in EAS patients so far are heterozy-
gous, and as the tetrameric NMDAR is formed of two GluN2 subunits and two GluN1, some receptors in the 
patients will most likely contain one copy of the mutation. We have reported the effects of receptors containing 
two mutant GluN2A copies, as others have done so, but hypothesize that those with one mutant copy will have an 
intermediate phenotype for agonist affinity38, but remain the same for surface expression34. Another limitation is 
that we have so far only studied the effect of the mutations in a heterologous cell line. HEK-293 are a common and 
well-validated model for the study of membrane ion channels as they do not contain other channels that need to 
be blocked, simplifying assay conditions. However, analysis in a more native environment could potentially offer 
further insights into the effects of the mutations, although they would still need to be overexpressed. We would 
expect the mutations studied here to have similar effects on NMDAR trafficking and agonist potency in cultured 
primary neurons, as others have shown translational results26, 34. Additional studies will aid clarification of this 
hypothesis.
We did not find any effects of the mutations I814T, D933N and N976S on the function of NMDARs, however 
this is not to say that they do not exert an effect on the protein. The C-terminal of GluN2A couples to diverse 
intracellular cascades such as for scaffolding and post-synaptic signaling, and post-translational modifications 
are important here14, 39. Further work may determine their associations with these residues. Given the low CADD 
score of N976S, and the fact that it is the only missense variant reported in two unrelated cases to date, it may be 
that it is a very rare benign variant; however, it has not been reported so far in any control population.
We rescued the function of receptors with reduced glutamate potency by incubation with a novel 
GluN2A-specific PAM. Due to the differing magnitudes of effect of the mutants on agonist potency, it can be 
seen that different concentrations of the PAM would be needed for perfect restoration of function. The function 
of D731N could not be restored by this method, presumably because glutamate does not bind to this mutant. 
The search for new potentiators for clinical enhancement of NMDAR function has been sporadic. However, 
with NMDAR hypofunction now shown here to be a disease mechanism in epilepsy, as well as schizophrenia40, 
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cognitive decline and Alzheimer’s disease41, this may be changing42. Rescue of mutant receptors that are trapped 
within the ER may also be possible using cell-and-ER permeable competitive antagonists, as has been achieved 
for D732A-GluN1 using the competitive glycine site antagonist DCKA32, however cell permeability may be an 
issue for GluN2A-specific antagonists.
The mutations studied here show a range of phenotypic deficits, and combined with the work of others indi-
cate a complex picture of molecular consequences. Modern translational medicine techniques will be needed to 
identify patient mutations through high-throughput sequencing, and confirm the type of molecular dysfunction 
before the identification of potential therapeutic compounds in vitro. This strategy of personalized medicine may 
allow for a repositioning of certain approved-compounds and a reduction in the number of antiepileptic medica-
tions used, and could dramatically alter disease progression and the development of the affected child.
Methods
Selection of mutants and functional hypotheses. 31 missense mutations from individuals with EAS 
disorders15–17 were assigned Combined Annotation Dependent Depletion (CADD) scores20 using the web tool 
http://cadd.gs.washington.edu/ v1.3 to create predictions of deleteriousness. These CADD scores were compared 
to those for controls from the Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/ assessed 05/2016) 
where 65/6474 individuals sequenced across GRIN2A had a missense variant. A scaled CADD score cut off of 20 
was used to indicate a variant as highly likely to be deleterious.
A contribution to the selection of the mutants included here was a hypothesis of the function of each mutant 
based on their location in available structures of GluN2A (or homologous GluN2B structures). P79R is present 
in the NTD, this mutation was hypothesised to affect the conformation of that region of the protein, in addition 
to affecting the contacts that the proline residue has with GluN1. C231Y is also present in the NTD, this muta-
tion causes a significant change in residue size and was hypothesised to affect the conformation of this region of 
the protein. C436R is present in the ABD and is involved in a disulfide bond; this mutation was hypothesised to 
be highly destabilizing. G483R is present in the ABD in close proximity to the glutamate binding site and thus 
predicted to affect binding affinity. M705V is present in the ABD, albeit slightly further away from the glutamate 
binding site; some protein conformational change was hypothesised. E714K is present in the ABD, but on the 
protein surface. In some crystal structures it is not full resolved suggesting it is flexible and non-essential for 
protein stability, thus a limited effect on glutamate binding was hypothesised. D731N is present in the ABD 
and forms a direct contact to glutamate via a salt bridge; this mutation was hypothesised to have a significant 
effect on glutamate binding although the protein was expected to still be able to fold correctly. I814T is present 
on the linker between the ABD and TMD, the effect of this mutation was unclear from a structural perspective. 
Mutations D933N and N976S are both present in the CTD and are not structurally characterized so hypotheses 
could not be generated.
DNA constructs. Human GRIN2A (GenBank accession: NM_000833.3) cDNA clone was purchased from 
OriGene Technologies (Cat#: SC122120). The various mutants of GRIN2A and insertion of the HA-tag into 
GRIN2A were generated by PCR-based mutagenesis using the wild-type cDNA clone as template. Mutations 
inserted were: P79R, C231Y, C436R, G483R, M705V, E714K, D731N, I814T, D933N and N976S. The nucleotide 
sequences encoding full-length wild-type and various mutants were inserted into pcDNA3.1 (+) (Invitrogen) 
with the cytomegalovirus (CMV) enhancer-promoter for high expression, and verified by DNA sequencing. 
Human GRIN1 (GenBank accession NM_000832.5) cDNA clone was also purchased from Origene Technologies 
(Cat#: SC308819) and inserted into a second pcDNA3.1 (+) vector. An empty pcDNA3.1 (+) vector was used 
as a control in the live cell imaging assays and co-transfected with the GRIN1 plasmid. Transfection efficiency 
was assessed in the calcium flux assay as the number of HEK cells responding to maximal glutamate (Fig. 4e) vs. 
those responding to MgATP, as NMDAR can only function if both GRIN1 and GRIN2A plasmids transfect and 
express the protein.
Cell culture and transient transfection. HEK-293 cells were cultured in high glucose DMEM medium 
(Gibco) containing 2 mM penicillin/streptomycin and glutamine (Gibco) and 5% bovine calf serum (Gibco). Cells 
were plated at a density of 3 × 104 cells/well in 96-well black-walled poly(D)-lysine coated plates (Corning) with 
the addition of 1mM Ketamine (Sigma) in the culture media. Cells were transfected using 0.4 µl Lipofectamine 
2000 (ThermoFisher) per well, with 320 ng GRIN1 construct and 320 ng of a GRIN2A construct. Transfection with 
GRIN1 is presumed in the figure legends. For the transfection assay (Fig. 5f), varying amounts of WT GRIN2A 
plasmid (320, 160, 80, 40 and 20 ng) were added per well, along with 320 ng GRIN1. Cells were kept in an incuba-
tor at 37 °C and 5% CO2 and used for all assays 48-hours after plating and transfection.
Continuous live cell imaging – cell toxicity assay. HEK-293 cells were seeded and transiently trans-
fected as detailed above, but without Ketamine in the culture media. Cytotox-Red dye (Essen BioScience) was 
added to each well to 1:400 dilution for labelling of nucleic acids in dead cells upon excitation at 585 nm. Plates 
were imaged one field per well every 6 hours in the Incucyte ZOOM live cell imaging system (Essen BioScience) 
for 48 hours. Images were analysed with the Incucyte ZOOM software and data normalised to the initial conflu-
encey of cells in each well to control for inter-well plating variability.
Calcium flux assays. HEK-293 cells were seeded and transiently transfected as detailed above. After 
48 hours, media was removed and 100 µl of buffer containing the cell-permeant calcium binding dye at 4 µM, 
Fluo-4 AM (ThermoFisher), 0.1% pluronic acid (ThermoFisher) and 1mM Ketamine was added per well. Details 
of the buffers and method used for the single cell calcium flux imaging are as in22. A modified HEPES-buffered 
Tyrode’s solution (HBTS) (Invitrogen) was used throughout the experiments and called “perfusion buffer”, con-
taining (mM): 135 NaCl, 5 KCl, 2.5 CaCl2, 10 HEPES, 10 glucose, pH 7.2). Transfected cells were identified as 
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responding to compound addition due to fluorescence of the Fluo-4 AM dye upon calcium influx into the cells. 
Data were analysed by averaging individual traces collected from cells in multiple wells of the 96-well plate. 
N = well number, and number of experiments is listed below each figure. Nonlinear regression using the least 
squares fit of the log(agonist) vs. response – variable slope (four parameters) was applied to the fluorescence 
intensity values with background removed, and were normalised to the maximal response for each mutant.
For all assays described below, compounds are diluted in perfusion buffer and glycine (Tocris) is at 30 µM 
unless otherwise stated. For the glutamate CRC assays, increasing concentrations of glutamate (ranging from 
30 nM to 30 µM) (Sigma) were perfused over the cells every 30 seconds, whilst keeping constant 30 µM glycine. 
For the glycine CRC assays, increasing concentrations of glycine from 30 nM to 30 µM were perfused over the 
cells, with constant 3 µM glutamate. For the cell counting assay, initially 100 µM glutamate with 30 µM glycine 
were perfused over the cells for 30 seconds, followed by a wash for 3 minutes and then perfusion with 100 µM 
MgATP (Sigma) for 30 seconds. The GluN2A-selective PAM was synthesized in-house following the structure of 
the compound named “example 275” from the referenced patent application23. The structure of the compound is 
listed in the patent, and the potency for GluN2A is listed with an EC50 of 12 nM. This compound is subsequently 
referred to as the PAM. For the assays using the PAM, two different protocols were used, as described in Fig. 6.
Patch Clamp Recordings. Whole–cell voltage clamp recordings were carried out on transfected HEK-293 
cells at a holding potential of −60 mV (at 21 °C) using an Axopatch 200A amplifier (Molecular Devices). Current 
data were recorded at 10 kHz using a DA/AD interface (Digidata 1322A, Molecular Devices). Patch pipettes were 
pulled using a horizontal puller (Sutter Instruments) from thin-walled borosilicate glass (Harvard apparatus, 
Ltd.) that gave resistances between 4 and 7 MΩ when filled with the intracellular electrode solution. The pipette 
solution comprised of (in mM) 140 K-Gluconate, 1 MgCl2, 4 MgATP, 0.5 EGTA, 10 HEPES, (adjusted to pH 7.3 
with KOH, all Sigma). Cells were perfused with the same perfusion buffer used in the calcium flux assay contain-
ing 30 µM glycine, and glutamate from 30 nM to 30 µM as detailed in Fig. 3, using a multichannel perfusion sys-
tem (Model BPS-8, Scientifica). Transfected cells were identified by an initial large response to maximal glutamate 
and glycine and used for subsequent recording protocols.
Western Blotting. HEK-293 cells were harvested 48-hours after transient transfection. Proteins were 
extracted using RIPA buffer (Sigma) with Halt phosphatase inhibitor (ThermoFisher) and protease inhibitor cock-
tail (Calbiochem) for 10 minutes on ice. Proteins (4 µg/well) were prepared in 1xLaemmli buffer (Bio-Rad) and 
5% β-mercaptoethanol (Sigma), heated at 37 °C for 15 min and resolved on a 3–8% Tris-acetate NuPAGE Novex 
gel (ThermoFisher). Proteins were then transferred onto Hybond-ECL nitrocellulose membrane (Amersham) 
which was cut on the 38 kDa marker and the top part (>38 kDa) incubated with anti-GluN2A antibody (M264, 
Sigma) at 1:1000 and the bottom part with anti-GAPDH antibody (AM4300, Ambion) 1:10,000. Primary anti-
bodies were detected with horseradish peroxidase conjugated anti-rabbit (GluN2A) and anti-mouse (GAPDH) 
antibodies (Sigma) at 1:10,000 dilution, followed by signal development with SuperSignal West Dura reagent 
(ThermoFisher). Protein bands were detected on an Image Quant Las 400 Mini apparatus (GE Healthcare). 
Images were also obtained in the visible light spectrum for alignment of the molecular weight marker bands. 
Values reported are means of four different transfection, lysis and Western blotting experiments, i.e. N = 4.
Immunocytochemistry. 48-hours after transfection HEK cells were treated in two different ways: 1) For 
total GluN2A labelling, cells were fixed with 4% paraformaldehyde for 10 min before blocking/permeabilisa-
tion with 5% BSA (Thermo Fisher) 0.1% Triton X-100 (Sigma) in PBS for 30 min at room temperature. 2) For 
membrane-only staining, cells were blocked in PBS with 5% BSA and 1mM Ketamine for 1 hour at room temper-
ature. For both methods, HA-tagged GluN2A was immunolabelled using anti-HA antibody (H6908) at 5 µg/ml 
in PBS with 0.5% BSA, (and 0.1% Triton X-100 for the total GluN2A labelled cells), for 2 hours at 4 °C, followed 
by washing. The membrane-only cells were now fixed with 4% paraformaldehyde. Both cell types were then incu-
bated for 1.5 hours with Alexa Fluor 555-conjugated donkey-anti-rabbit secondary antibody at 1:1000 in the dark 
(A-31572, Thermo Fisher). Cells were finally then incubated for 10 min at room temperature with Hoechst 33342 
nuclear stain (Thermo Fisher). Stained cells were viewed by confocal microscopy using the Olympus FV1000. 
Image files were analysed by using Cell Profiler24. Briefly images were segmented by using the nuclear staining 
channel followed by measurement of average fluorescence intensity in the Alexa-555 channel.
Statistical Analysis. Data were analysed using Prism 5 (Graph Pad). Where appropriate, data were tested 
for normal distribution using the Kolmogorov-Smirnov test and passed. Alpha was 0.05. Analysis of statistical 
significance was assessed using either a one way ANOVA corrected for multiple testing with Dunnett’s correction 
for Figs 2c, 4e and 5d, and with Bonferroni correction for 6c, and the extra-sum-of-squares F-test of best-fit values 
of LogEC50 used for Figs 3c–f, 5f and 6e–h. Correlation between surface levels of Glu2NA expression and EC50 for 
the mutations was assessed using Pearson’s coefficient of determination in Fig. 5e.
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